Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net income (loss)	$ 28,067	$ (71,279)	$ (13,473)
Adjustments to reconcile net income (loss) to net cash flows from operating activities:
Depreciation, amortization and accretion	47,929	42,288	24,689
Impairment of long-lived assets	0	9,729	9,935
Asset retirement obligation acceleration	280	5,259	0
Gain on interest rate swap termination	(5,494)	0	0
Amortization of debt related costs	1,249	676	119
Changes in fair value of contingent assets and liabilities	34,700	72,400	(2,000)
Charges incurred in connection with acquired IPR&D	260,000	0	0
Loss (gain) on extinguishment of debt	588	(889)	0
Provision for excess and obsolete inventory	7,145	4,057	2,365
Stock-based compensation	29,262	15,934	14,075
(Gain) loss on disposal of assets	0	(15,263)	2,250
Deferred taxes	(48,016)	4,437	(1,334)
Long-term indemnification receivable	9,554	7,121	(2,218)
Long-term income tax payable and other long-term liabilities	(12,477)	(7,912)	2,828
Other	4,059	2,512	1,525
Increases (decreases) in cash from operating assets and liabilities:
Accounts receivable	(128,460)	(33,102)	(7,462)
Inventory	(7,508)	(3,549)	(8,459)
Other current assets	(2,440)	(73)	1,941
Other long-term assets	(533)	0	0
Accounts payable	301	5,425	(4,224)
Accrued expenses and other liabilities	63,575	16,145	(4,161)
Net cash provided by operating activities	281,781	53,916	16,396
Investing activities
Capital expenditures	(18,347)	(12,140)	(12,474)
Proceeds from sale of assets, net	1,800	15,823	0
Acquisition of assets	(260,000)	0	0
Lending on bridge loan	0	0	(10,000)
Cash acquired in acquisition of business	0	0	17,562
Net cash (used in) provided by investing activities	(276,547)	3,683	(4,912)
Financing activities
Proceeds from issuance of common stock	1,375	767	683
Equity issuance costs	0	0	(3,777)
Debt issuance costs	(95)	0	0
Proceeds from issuance of long-term debt, net	557,750	0	0
Payments on long-term debt and other borrowings	(175,385)	(43,348)	(15,491)
Deferred financing costs	(2,315)	0	(1,224)
Proceeds from interest rate swap termination	5,583	0	0
Proceeds from stock option exercises	7,537	5,295	77
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(7,759)	(2,046)	(2,129)
Repurchase of common stock	(75,000)	0	0
Net cash provided by (used in) financing activities	311,691	(39,332)	(21,861)
Effect of foreign exchange rates on cash and cash equivalents	(335)	(310)	152
Net increase (decrease) in cash and cash equivalents and restricted cash	316,590	17,957	(10,225)
Cash and cash equivalents and restricted cash, beginning of year	100,651	82,694	92,919
Cash and cash equivalents and restricted cash, end of year	417,241	100,651	82,694
Reconciliation to amounts within the consolidated balance sheets
Cash and cash equivalents	415,652	98,508	79,612
Cash and cash equivalents included in assets held for sale	0	0	941
Restricted cash included in other long-term assets	1,589	2,143	2,141
Cash, cash equivalents and restricted cash at end of period	417,241	100,651	82,694
Supplemental disclosure of cash flow information
Interest	5,064	6,284	9,368
Income taxes, net of refunds of $50, $315 and $331, respectively	54,049	215	340
Schedule of non-cash investing and financing activities
Additions of property, plant and equipment included in liabilities	2,370	1,262	2,227
Consideration transferred in acquisition	$ 0	$ 0	$ 419,009